**IMPORTANT SCIENTIFIC INFO**
Will the cannabinoid creme work on Psoriasis?
This is the #1 question I ask myself and every shareholder should be focused on the upcoming clinical results. To be seen as effective from a patient's point-of-view, the creme will need to reduce redness, inflammation, pain and the itch. 2007 [UK] Cannabinoids may be useful for psoriasis, as THC, cannabidiol, cannabinol, and cannabigerol have been found to inhibit keratinocyte proliferation in hyperproliferating human keratinocyte cell lines.
Pain and itch are two irritating sensations sharing a lot in common.
2005 [Croatia] In a study of patients with a chronic itching that occurs in patients with advanced kidney disease, topical application of a cannabinoid creme applied twice daily for 3 weeks completely eliminated itching in 8 of 21 patients (38%). Another study of 22 patients reduced itch by 86.4% when topically administered.
Psoriasis, an autoimmune disease is characterized by an abnormally excessive and rapid growth of the epidermal layer of the skin.
Skin cells are replaced every 3–5 days in psoriasis rather than the usual 28–30 days. These changes are believed to stem from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells (three subtypes of white blood cells). 2013 [Germany] In mice, topical THC application effectively decreased contact allergic ear swelling and myeloid immune cell infiltration which influences inflammation. Topical THC limited myeloid immune cell recruitment by a decreasing T-cell production of interferon-y and keratinocyte production of CCL2, CCL8, and CXL10 chemokines. In terms of atopic dermatitis, the activation of CB1 receptors in mice has been found to improve epidermal barrier function, decrease Th2-mediated inflammatory response, and suppress mast cells. Mast cells (type of white blood cell) play a key role in the inflammatory process.
Although there are existing reports and studies on CBD and THC (on mice and humans), OWC's formulations will contain several active compounds from the cannabis plant, that must be fully researched and documented (but not exclusive to) the cannabinoids CBD and THC, and identifying potential therapeutic applications of the synergistic effects of these active compounds. THC may also demonstrate anti-inflammatory effects independent of CB1 and CB2 receptors, which needs to be further studied and I believe they are doing it right now.
What other skin conditions have most similar symptoms?
Acne
Basal cell carcinoma
Allergic contact dermatitis
Atopic dermatitis
Contact dermatitis
Eczema
Conclusion:
Based on the preliminary studies I believe OWC's psoriasis creme will reduce pain, inflammation and irritation in psoriasis patients. They will be able to adjust the formulations to determine the most effective syngergistic effects of several cannabinoids (not just CBD/THC). The more I look into the science, the more confident I am that this investment is well deserved and the research on the subject just isn't what it should be. OWC is on the frontier of these breakthroughs and the most valuable asset OWC will have is the intellectual property of their formulations. Have a great day and enjoy the holiday! Happy 4/20 everyone!
Which interleukins is OWC focusing on?
IL1, IL2, IL3, IL8, IL10, IL13, IL15, IL17, IL20, IL23
IFN-gamma
TNF-alpha
IL1 participates in the regulation of immune responses, inflammatory reactions and hematopoiesis (formation of blood cells).
IL2 regulates the growth and differentiation of T cells and certain B cells through the release of secreted protein factors. (T-cells cause inflammation, activate macrophages and get other T-cells fired up, regulate much of the immune response) (Types of T-cells include Helper, Cytotoxic, Memory, Suppressor, Natural Killer).
IL3 regulates hematopoiesis by controlling production, differentiation and function of granulocytes and macrophages.
IL8 induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection.
IL10 is a protein that inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF, and GM-CSF produced by activated macrophages and by helper T cells.
IL13 is a pleiotropic cytokine that may be important in the regulation of the inflammatory and immune responses.
IL15 is a cytokine that possesses a variety of biological functions, including stimulation and maintenance of cellular immune responses
IL17 is a potent proinflammatory cytokine produced by activated memory T cells.
IL20 regulates proliferation and differentiation of keratinocytes.
IL23 maintenance of IL-17 producing cells, increases angiogenesis but reduces CD8 T-cell infiltration
IFN-gamma (interfering gamma activates macrophages and they turn into granulomas).
TNF-alpha is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. It is produced chiefly by activated macrophages.
Conclusion:
There is more to the science than some would imagine. It is extremely complex and scientists are still making huge discoveries in this field. OWC is quickly getting their cream formulated and out to market to generate revenue ASAP. That is how confident they are in the research and product potential. As more studies are done and funded by the sales of creme via licensing, OWC will garner huge respect from the industry as they increase and secure their IP portfolio.
Sources:
http://www.ct.gov/dcp/lib/dcp/pdf/mmp/cannabi...ocytes.pdf
http://onlinelibrary.wiley.com/doi/10.1111/all.12183/full
https://link.springer.com/article/10.1007/s00702-014-1251-x
https://en.wikipedia.org/wiki/Interleukin#Lis...terleukins
www.owcpharma.com/newsroom-photos/ (CFN Interview with Dr. Yehuda Baruch)
https://www.youtube.com/watch?v=aYNgLQNpA6E (Psoriasis and beyond: targeting the IL-17 pathway)
Will the cannabinoid creme work on Psoriasis?
This is the #1 question I ask myself and every shareholder should be focused on the upcoming clinical results. To be seen as effective from a patient's point-of-view, the creme will need to reduce redness, inflammation, pain and the itch. 2007 [UK] Cannabinoids may be useful for psoriasis, as THC, cannabidiol, cannabinol, and cannabigerol have been found to inhibit keratinocyte proliferation in hyperproliferating human keratinocyte cell lines.
Pain and itch are two irritating sensations sharing a lot in common.
2005 [Croatia] In a study of patients with a chronic itching that occurs in patients with advanced kidney disease, topical application of a cannabinoid creme applied twice daily for 3 weeks completely eliminated itching in 8 of 21 patients (38%). Another study of 22 patients reduced itch by 86.4% when topically administered.
Psoriasis, an autoimmune disease is characterized by an abnormally excessive and rapid growth of the epidermal layer of the skin.
Skin cells are replaced every 3–5 days in psoriasis rather than the usual 28–30 days. These changes are believed to stem from the premature maturation of keratinocytes induced by an inflammatory cascade in the dermis involving dendritic cells, macrophages, and T cells (three subtypes of white blood cells). 2013 [Germany] In mice, topical THC application effectively decreased contact allergic ear swelling and myeloid immune cell infiltration which influences inflammation. Topical THC limited myeloid immune cell recruitment by a decreasing T-cell production of interferon-y and keratinocyte production of CCL2, CCL8, and CXL10 chemokines. In terms of atopic dermatitis, the activation of CB1 receptors in mice has been found to improve epidermal barrier function, decrease Th2-mediated inflammatory response, and suppress mast cells. Mast cells (type of white blood cell) play a key role in the inflammatory process.
Although there are existing reports and studies on CBD and THC (on mice and humans), OWC's formulations will contain several active compounds from the cannabis plant, that must be fully researched and documented (but not exclusive to) the cannabinoids CBD and THC, and identifying potential therapeutic applications of the synergistic effects of these active compounds. THC may also demonstrate anti-inflammatory effects independent of CB1 and CB2 receptors, which needs to be further studied and I believe they are doing it right now.
What other skin conditions have most similar symptoms?
Acne
Basal cell carcinoma
Allergic contact dermatitis
Atopic dermatitis
Contact dermatitis
Eczema
Conclusion:
Based on the preliminary studies I believe OWC's psoriasis creme will reduce pain, inflammation and irritation in psoriasis patients. They will be able to adjust the formulations to determine the most effective syngergistic effects of several cannabinoids (not just CBD/THC). The more I look into the science, the more confident I am that this investment is well deserved and the research on the subject just isn't what it should be. OWC is on the frontier of these breakthroughs and the most valuable asset OWC will have is the intellectual property of their formulations. Have a great day and enjoy the holiday! Happy 4/20 everyone!
Which interleukins is OWC focusing on?
IL1, IL2, IL3, IL8, IL10, IL13, IL15, IL17, IL20, IL23
IFN-gamma
TNF-alpha
Quote:"We have proven that it inhibits proliferation of keratinocytes. We are working on how does it manage in certain interleukins which cause inflammation. We are looking at the various interleukins to see what does medical cannabis, especially THC & CBD, do to those various interleukins. We have got already primary results. This study will be finished by the end of April and we can have the results published."
*CFN Interview with Dr. Yehuda Baruch, Chief Science Officer OWCP, starts at 2:57.
IL1 participates in the regulation of immune responses, inflammatory reactions and hematopoiesis (formation of blood cells).
IL2 regulates the growth and differentiation of T cells and certain B cells through the release of secreted protein factors. (T-cells cause inflammation, activate macrophages and get other T-cells fired up, regulate much of the immune response) (Types of T-cells include Helper, Cytotoxic, Memory, Suppressor, Natural Killer).
IL3 regulates hematopoiesis by controlling production, differentiation and function of granulocytes and macrophages.
IL8 induces chemotaxis in target cells, primarily neutrophils but also other granulocytes, causing them to migrate toward the site of infection.
IL10 is a protein that inhibits the synthesis of a number of cytokines, including IFN-gamma, IL-2, IL-3, TNF, and GM-CSF produced by activated macrophages and by helper T cells.
IL13 is a pleiotropic cytokine that may be important in the regulation of the inflammatory and immune responses.
IL15 is a cytokine that possesses a variety of biological functions, including stimulation and maintenance of cellular immune responses
IL17 is a potent proinflammatory cytokine produced by activated memory T cells.
IL20 regulates proliferation and differentiation of keratinocytes.
IL23 maintenance of IL-17 producing cells, increases angiogenesis but reduces CD8 T-cell infiltration
IFN-gamma (interfering gamma activates macrophages and they turn into granulomas).
TNF-alpha is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. It is produced chiefly by activated macrophages.
Conclusion:
There is more to the science than some would imagine. It is extremely complex and scientists are still making huge discoveries in this field. OWC is quickly getting their cream formulated and out to market to generate revenue ASAP. That is how confident they are in the research and product potential. As more studies are done and funded by the sales of creme via licensing, OWC will garner huge respect from the industry as they increase and secure their IP portfolio.
Sources:
http://www.ct.gov/dcp/lib/dcp/pdf/mmp/cannabi...ocytes.pdf
http://onlinelibrary.wiley.com/doi/10.1111/all.12183/full
https://link.springer.com/article/10.1007/s00702-014-1251-x
https://en.wikipedia.org/wiki/Interleukin#Lis...terleukins
www.owcpharma.com/newsroom-photos/ (CFN Interview with Dr. Yehuda Baruch)
https://www.youtube.com/watch?v=aYNgLQNpA6E (Psoriasis and beyond: targeting the IL-17 pathway)
